GALANTAMINE ZENTIVA LAB LP 8 mg, extended-release capsule 28 capsules
Active ingredients: Galantamine hydrobromide, Galantamine
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release capsule28 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- GALANTAMINE ZENTIVA LAB LP 8 mg, gélule à libération prolongée
- Pharmaceutical form
- gélule à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) PVC polyéthylène PVDC aluminium de 28 gélule(s)
- Marketing authorisation holder
- ZENTIVA FRANCE
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 Mar 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Initial prescription by a specialist
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66284291CIP72197188CIP133400921971880Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| BROMHYDRATE DE GALANTAMINEgélule | — | SA |
| GALANTAMINEgélule | 8 mg · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.